The procedures took place as part of the commencement of a clinical trial in India. Tria remains investigational and not available for commercial sale.
Salt Lake City-based Foldax designed Tria to accommodate the anatomy and pressures of the mitral position. It combines the company’s proprietary LifePolymer with a valve design for resisting calcification. The company says its valve withstands stresses and strains without failure, restoring quality of life without lifelong anticoagulant use.
According to Foldax, currently available prosthetic valve options for treating mitral valve disease have limitations. Those include issues with durability for tissue valves made from porcine or pericardial tissue. Additionally, some countri…